Intensity Therapeutics utilizes its proprietary DfuseRx℠ intratumoral delivery technology to inject therapeutic agents directly into solid tumors, enhancing drug absorption and promoting localized cancer cell death. This approach activates a systemic immune response, targeting both the primary tumor and metastatic sites, ultimately aiming to extend patient survival and reduce disease recurrence.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors are difficult to treat effectively because systemic drug delivery fails to achieve sufficient drug concentrations within the tumor microenvironment. This limitation hinders the ability of chemotherapeutic agents to induce cancer cell death and stimulate a robust immune response.
Solution
Intensity Therapeutics is developing a technology, DfuseRx, that enables direct injection of therapeutic agents into solid tumors, enhancing drug dispersion and absorption within the tumor. This intratumoral delivery approach promotes localized cancer cell death in a manner that facilitates immune cell infiltration. The resulting release of tumor-associated antigens stimulates a systemic, personalized T-cell response, targeting both the injected tumor and distant metastatic sites. This approach aims to improve patient survival and reduce disease recurrence.
Target Audience
The primary target audience includes patients with relapsed, refractory, or metastatic solid tumors, as well as those undergoing presurgical treatment for cancer.
Features
- DfuseRx technology platform enhances the diffusion of injected drugs throughout the tumor mass.
- Induces cancer cell death without disrupting the cell membrane, promoting immune cell infiltration.
- Stimulates a personalized CD4+ and CD8+ T cell response against tumor-associated antigens.
- Targets both the primary injected tumor and distal metastatic sites.
- Investigational product, INT230-6, is being evaluated in clinical trials.